Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell has recorded its first commercial sales of Remplir in Canada, following Health Canada approval and the appointment of distributors that provide majority national coverage in a nerve repair market worth about US$75 million. The company has supported the launch with a key-opinion-leader roadshow to drive surgeon education and early adoption, underscoring the effectiveness of its capital-light, distributor-led model for non-U.S. markets.
Remplir is now approved and generating revenue in Australia, New Zealand, the U.S., Singapore, Hong Kong and Canada, with plans to enter the larger EU/UK market after anticipated approvals in the coming years. Well funded with more than A$48 million in cash and no debt, Orthocell is positioned to leverage growing access to around 336 U.S. hospitals, including 221 military medical centres, to increase Remplir utilisation and strengthen its position in the global nerve repair sector.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.24 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a Perth-based regenerative medicine company specialising in nerve repair medical devices, led by its flagship collagen-based Remplir implant. The company targets global nerve repair markets through a mix of distributor-led strategies in non-U.S. regions and a company-led approach in the U.S., supported by a strong cash position and no debt to fund ongoing commercial expansion.
Average Trading Volume: 417,199
Technical Sentiment Signal: Hold
Current Market Cap: A$230.6M
See more insights into OCC stock on TipRanks’ Stock Analysis page.